Sanofi to invest approx. $434M in new vax facility

April 13, 2018

Sanofi is investing €350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP), or whooping cough, antigen.

Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines.

Sanofi Pasteur enjoyed considerable success last year, seeing full year 2017 sales increasing 8.7 percent from 2016.  Polio/Pertussis/Hib sales grew by 15.3 percent.

Read the press release